1. Show article details.

    Caladrius Biosciences to Participate at the Upcoming October Conferences

    GlobeNewswire – 8:30 AM ET 10/01/2019

    Caladrius Biosciences, Inc. (CLBS), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will participate in the following conferences in October: 2019 Cell & Gene Meeting on the Mesa Dawson James Securities 5th Annual...

  2. Show article details.

    CORRECTING and REPLACING -- Caladrius Biosciences to Participate at the Upcoming September Conferences

    GlobeNewswire – 10:15 AM ET 09/06/2019

    In a release issued under the same headline yesterday by Caladrius Biosciences, Inc. (CLBS) please note that the date of the H.C. Wainwright conference should be Tuesday, September 10, not Thursday, September 12, and the Venue for Investing for Cures 2019 should be Club 101, 101 Park Avenue in New York, NY, not Lotte New York Palace Hotel, as previously stated.

  3. Show article details.

    Caladrius Biosciences to Participate at the Upcoming September Conferences

    GlobeNewswire – 4:05 PM ET 09/05/2019

    Caladrius Biosciences, Inc. (CLBS), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that management will participate in the following conferences in September: About Caladrius BiosciencesCaladrius is a late-stage therapeutics development biopharmaceutical company pioneering advan...

  4. Show article details.

    BRIEF-Caladrius Biosciences Reports Q2 Loss Per Share $0.49

    Reuters – 5:26 PM ET 08/08/2019

    Caladrius Biosciences Inc (CLBS): * CALADRIUS BIOSCIENCES REPORTS 2019 SECOND QUARTER AND FIRST SIX MONTHS FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE. * Q2 LOSS PER SHARE $0.49. * AS OF JUNE 30, 2019, CALADRIUS HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $33.7 MILLION Source text for Eikon: Further company coverage:

  5. Show article details.

    Caladrius Biosciences Reports 2019 Second Quarter and First Six Months Financial Results and Provides Corporate Update

    GlobeNewswire – 4:05 PM ET 08/08/2019

    Confirmatory Phase 3 Study Protocol Finalized for CLBS14 in No-Option Refractory Disabling Angina Conference call begins today at 4:30 p.m. Eastern time Caladrius Biosciences, Inc. (CLBS), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announces financial results for the three and six months en...

  6. Show article details.

    BRIEF-Caladrius Biosciences And Cognate Bioservices Establish Manufacturing Agreement For Phase 3 Confirmatory Pivotal Clinical Trial Of CLBS14

    Reuters – 9:24 AM ET 08/07/2019

    Caladrius Biosciences Inc (CLBS): * CALADRIUS BIOSCIENCES AND COGNATE BIOSERVICES ESTABLISH MANUFACTURING AGREEMENT FOR PHASE 3 CONFIRMATORY PIVOTAL CLINICAL TRIAL OF CLBS14 IN NO-OPTION REFRACTORY DISABLING ANGINA. * Caladrius Biosciences Inc (CLBS) - COGNATE WILL MANUFACTURE CLBS14 FOR CALADRIUS Source text for Eikon: Further company coverage:

  7. Show article details.

    Caladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina

    GlobeNewswire – 8:30 AM ET 08/07/2019

    Caladrius Biosciences, Inc. (CLBS), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, and Cognate BioServices, Inc., a leading contract development and manufacturing organization in the global cellular therapies industry, announced today that they have entered into a manufacturing agreement for th...

  8. Show article details.

    Caladrius Biosciences to Host 2019 Second Quarter Financial Results Conference Call on Thursday, August 8, 2019 at 4:30 p.m. Eastern Time

    GlobeNewswire – 8:30 AM ET 08/01/2019

    Caladrius Biosciences, Inc. (CLBS), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announces that the Company will release financial results for the six months ended June 30, 2019 after close of the U.S. financial markets on Thursday, August 8, 2019.

  9. Show article details.

    Caladrius Biosciences Receives Advanced Therapy Medicinal Product Classification for CLBS12, its CD34+ Cell Therapy for Critical Limb Ischemia

    GlobeNewswire – 8:30 AM ET 07/15/2019

    Caladrius Biosciences, Inc. (CLBS), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification to the Company’s CD34+ cell therapy product, CLBS12, for the treatment of critical limb ischemia.

  10. Show article details.

    Caladrius Biosciences Completes Enrollment in Phase 2 ESCaPE-CMD Trial for Coronary Microvascular Dysfunction

    GlobeNewswire – 8:30 AM ET 06/04/2019

    Caladrius Biosciences, Inc. (CLBS), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today the completion of enrollment and dosing in the Phase 2 ESCaPE-CMD study for CLBS16 in patients with coronary microvascular dysfunction.

  11. Show article details.

    Caladrius Biosciences Reports 2019 First Quarter Financial Results and Provides Corporate Update

    GlobeNewswire – 4:05 PM ET 05/09/2019

    All enrolling clinical programs advancing with top-line data expected in late 2019 and during 1H2020 for CLBS14-CMD and CLBS12, respectively CLBS14-NORDA phase 3 program targeted to begin enrollment in late 2019 Cash on hand projected to support existing programs through 2Q2020 Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., May 09, 2019 -- Caladrius Biosciences, Inc...

  12. Show article details.

    Caladrius Biosciences to Participate at the Upcoming May Conferences

    GlobeNewswire – 8:30 AM ET 05/07/2019

    Caladrius Biosciences, Inc. (CLBS), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select cardiovascular indications, announced today that management will participate in the following conferences in May: 16th International Symposium on ...

  13. Show article details.

    Caladrius Biosciences to Host 2019 First Quarter Financial Results Conference Call on Thursday, May 9, 2019 at 4:30 p.m. Eastern Time

    GlobeNewswire – 8:30 AM ET 05/02/2019

    Caladrius Biosciences, Inc. (CLBS), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select cardiovascular indications, announces that the Company will release financial results for the three months ended March 31, 2019 after close of the...

Page:

Today's and Upcoming Events

  • Nov
    06

    CLBS to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    08

    CLBS announced Q2 earnings.

Data provided by Thomson Reuters © 2019

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.